Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Anthony Turpin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2282-0101; OpenAlex author ID A5040360907. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 1, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 5 papers · 2024: 5 papers · 2025: 3 papers · 2026: 4 papers

Papers 29

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  3. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  4. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  5. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. Last author DOI 10.1002/jcsm.13595↗
  6. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  7. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  8. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  9. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  10. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  11. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. Co-author DOI 10.1186/s12957-024-03393-7↗
  12. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  13. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  14. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. Co-author DOI 10.1016/j.esmogo.2023.08.010↗
  15. Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Co-author DOI 10.1016/j.pan.2023.06.010↗
  16. Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221146132↗
  17. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  18. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  19. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  20. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Co-author DOI 10.1177/17588359221118019↗
  21. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2021.05.006↗
  22. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Last author DOI 10.1177/17588359211029825↗
  23. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  24. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Co-author DOI 10.1177/1758835920937949↗
  25. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Last author DOI 10.1634/theoncologist.2020-0577↗
  26. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Co-author DOI 10.3390/cancers12123866↗
  27. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. Co-author DOI 10.4251/wjgo.v12.i3.332↗
  28. [Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. Co-author DOI 10.1016/j.bulcan.2018.06.009↗
  29. Deep Vein Thrombosis: An Independent Poor Prognosis Factor of Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.11135↗

Trials 1

  1. Prognostic and Predictive Markers of Treatment Response in Patients With PAC. Principal investigator NCT05776342↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 13 shared papers, 2020–2026 · strength 2.13
  2. Jean‐Baptiste Bachet · 9 shared papers, 2020–2026 · strength 1.56
  3. Jerome F. Cros · 8 shared papers, 2022–2026 · strength 1.47
  4. Rémy Nicolle · 6 shared papers, 2022–2026 · strength 1.12
  5. Nelson Dusetti · 6 shared papers, 2022–2026 · strength 1.12
  6. Cindy Neuzillet · 7 shared papers, 2018–2025 · strength 1.11
  7. Louis de Mestier · 6 shared papers, 2020–2026 · strength 0.96
  8. Olivier Bouché · 6 shared papers, 2021–2026 · strength 0.88
  9. Aurélien Lambert · 5 shared papers, 2022–2026 · strength 0.85
  10. Nicolas Williet · 5 shared papers, 2021–2026 · strength 0.79
  11. Juan Iovanna · 4 shared papers, 2024–2026 · strength 0.76
  12. Thierry Conroy · 4 shared papers, 2024–2026 · strength 0.74
  13. James Biagi · 4 shared papers, 2024–2026 · strength 0.74
  14. Daniel John Renouf · 4 shared papers, 2024–2026 · strength 0.74
  15. Vinciane Rebours · 4 shared papers, 2021–2026 · strength 0.64
  16. Stéphanie Truant · 4 shared papers, 2016–2024 · strength 0.56
  17. Alexandre Harlé · 3 shared papers, 2024–2026 · strength 0.55
  18. Alice Boilève · 3 shared papers, 2023–2025 · strength 0.52
  19. Emmanuel Mitry · 3 shared papers, 2024–2026 · strength 0.51
  20. Christelle d’Engremont · 4 shared papers, 2020–2026 · strength 0.50
  21. Mehdi El Amrani · 3 shared papers, 2020–2024 · strength 0.47
  22. Camille Evrard · 3 shared papers, 2022–2026 · strength 0.47
  23. Pauline Parent · 2 shared papers, 2025–2026 · strength 0.44
  24. Déwi Vernerey · 3 shared papers, 2020–2025 · strength 0.43
  25. David Tougeron · 3 shared papers, 2022–2024 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.